Metastatic melanoma: a new molecule for early care and diagnosis

Melanoma is a very aggressive carcinoma and often effective at conventional therapies, therefore its precocity is the inhibition of its ability to metastasize the main objectives in the development of new therapeutic and diagnostic strategies. The collaboration between two Cnr institutes, the Institute of Biostructures and Bioimaging of Naples (Ibb-Cnr) and the Institute of Crystallography of Bari (Ic-Cnr), the University of Naples Federico II and the University of Campania Luigi Vanvitelli has led to the development of a new molecule of peptide nature, able to selectively link a known tumor marker (Integrina αvβ3) and to visualize it by optical imaging, as well as to inhibit the invasion and the neoplastic progression in cellular systems of metastatic melanoma Human. The results, published in the Journal of medicinal chemistry, the prestigious journal of the American Chemical Society, open the door to the use of peptide as a probe and therapeutic agent for the early diagnosis and treatment of invasive forms of melanoma.